Please login to the form below

Not currently logged in
Email:
Password:

Nestlé acquires CM&D Pharma

Nestlé Health Science has acquired CM&D Pharma, a small UK company specialising in kidney disease, inflammatory bowel disease and colon cancer

Nestlé Health Science has acquired CM&D Pharma, a small UK company specialising in the research and development, marketing and sales of foods for specialist medical purposes. The company's portfolio comprises products tailored for patients with kidney disease, inflammatory bowel disease and colon cancer.

The financial details of the acquisition, which took place just one month after Nestle Health Science became operational, have not been disclosed. Nestlé Health Science is a fully-owned subsidiary of Nestlé SA and will develop science-based nutritional solutions to deliver personalised healthcare for medical conditions.

Commenting on the deal, Luis Cantarell, president and CEO of Nestlé Health Science said: "This acquisition is an excellent fit with Nestlé Health Sciences strategic goal of being a pioneer in the promising area of science-based nutrition. We share CM&D's commitment to use health science for improving the quality of people's lives, and this acquisition will help to reinforce our position in this opportunity. Additionally, CM&D will benefit from Nestlé Health Science's commitment to biomedical research, and the resources of the Nestlé Institute of Health Sciences." 

CM&D's leading product is Fostrap, a medical chewing gum for kidney patients with hyperphosphataemia (an elevated level of phosphate in the blood). Its other products include Reclonix for the treatment of abdominal pain often associated with Crohn's Disease; ulcerative colitis; or non-specific inflammatory bowel disease and Eviendep, a unique colon protector is intended to slow down the progression of polyps to colon cancer and to prevent their reoccurrence following removal.

CM&D founder, Danilo Casadei Massari, commented: "The Board of CM&D Pharma is confident that now, with a trade shareholder with unparallelled expertise and understanding of the science and the regulatory environment behind dietary management of health conditions, its product portfolio will be fully exploited.  We are also pleased to have maintained our promise to our original shareholders, and rewarded them for their faith in us."

Fasken Martineau LLP acted as legal adviser to CM&D on the transaction. 

3rd February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The new pharma marketing playbook
Learn about the 5 areas that must be in your pharma marketing playbook...
Pharma needs to evolve from customer-centricity to stakeholder-centricity
Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
5 health behavioural factors to incorporate in your marketing
Achieve real health behaviour change by including these elements in your pharmaceutical marketing....

Infographics